Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer

NCT02819999 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT02819999
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02819999 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Terminated
Start date
October 31, 2016
Completion date
May 31, 2019
Enrollment
28 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung cancer